A Pilot Clinical Trial of Oral Tetrahydrouridine/Decitabine for Non-Cytotoxic Epigenetic Therapy of Chemo-resistant Lymphoid Malignancies

One mechanism by which lymphoid malignancies resist standard apoptosis-intending (cytotoxic) treatments is genetic attenuation of the p53/p16-CDKN2A apoptosis axis. Depletion of the epigenetic protein DNA methyltransferase 1 (DNMT1) using the deoxycytidine analog decitabine is a validated approach t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Semin Hematol
Autors principals: Hill, Brian, Jagadeesh, Deepa, Pohlman, Brad, Dean, Robert, Parameswaran, Neetha, Chen, Joel, Radivoyevitch, Tomas, Morrison, Ashley, Fada, Sherry, Dever, Meredith, Robinson, Shelley, Lindner, Daniel, Smith, Mitchell, Saunthararajah, Yogen
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7847482/
https://ncbi.nlm.nih.gov/pubmed/33509441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminhematol.2020.11.008
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars